At a glance
During this COCA Call, CDC experts will present updated recommendations on COVID-19 vaccines for people who are moderately or severely immunocompromised.
Webinar
"This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention."
Overview
During this COCA Call, CDC experts will present:
- Updated recommendations on COVID-19 vaccines for people who are moderately or severely immunocompromised,
- Simplified recommendations for vaccination following receipt of passive antibody therapy, and
- Summarized recommendations for COVID-19 vaccination by age group.
Presenters
Sara Oliver, MD MSPH
LCDR, U.S. Public Health Service
Lead, Advisory Committee for Immunization Practices COVID-19 Vaccines Work Group
COVID-19 Response
Centers for Disease Control and Prevention
Elisha Hall, PhD, RD
Lead, Clinical Guidelines Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention
Evelyn Twentyman, MD, MPH
Chief Medical Officer, Vaccine Task Force
COVID-19 Response
Centers for Disease Control and Prevention
Call Objectives
Activity-specific objectives:
- Discuss current recommendations related to COVID-19 vaccination for people who are moderately or severely immunocompromised.
- Describe the simplified recommendations for COVID-19 vaccination after a patient has received passive antibody therapy.
- List key points for healthcare providers to use when talking about COVID-19 vaccination with people who are moderately or severely immunocompromised and with people who have received passive antibody therapy.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC's role in the topic covered during the presentation.
- Describe the topic's implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
Continuing Education
To receive continuing education (CE) for WC4520-050522 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Evaluating and Supporting Patients Presenting with Cognitive Symptoms Following COVID, Thursday, May 5, 2022, please visit TCEO and follow these 9 Simple Steps by Monday, June 6, 2022.
To receive continuing education (CE) for WD4520-050522 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Evaluating and Supporting Patients Presenting with Cognitive Symptoms Following COVID, Thursday, May 5, 2022, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, June 7, 2022, and Friday, June 7, 2024
In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-22-032-L04-P and enduring JA4008229-0000-22-033-H04-P.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession.
For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, with the exception of Dr. Talya Fleming who would like to disclose that she received a research grant from NuStep and served as co-principal investigator for Stroke Rehabilitation Clinical Research Trial. All grant funds are received and managed by hospital organization.
All of the relevant financial relationships listed for this individual has been mitigated.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
Target Audience
- Physicians
- Nurses
- Pharmacists
- Veterinarians
- Physician Assistants
- Health Educators
- Other Clinicians
Additional Information
- Contact Information: coca@cdc.gov
- Support/Funding: Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation: You may participate in the educational activity by viewing the program information above.